{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:48:21Z","timestamp":1780930101668,"version":"3.54.1"},"reference-count":48,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.2217\/fmb-2018-0054","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T10:28:08Z","timestamp":1524652088000},"page":"971-983","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":40,"title":["Meropenem\u2013Vaborbactam: A New Weapon in the War Against Infections Due to Resistant Gram-Negative Bacteria"],"prefix":"10.1080","volume":"13","author":[{"given":"Twisha S","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Michigan Medicine, Ann Arbor, MI48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M","family":"Pogue","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Sinai-Grace Hospital, Detroit, MI482351, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Mills","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,4,25]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/677157"},{"key":"e_1_3_3_4_1","unstructured":"World Health Organization . Antimicrobial resistance global report on surveillance (2014). http:\/\/apps.who.int\/iris\/bitstream\/10665\/112642\/1\/9789241564748_eng.pdf?ua=1 ."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.2080"},{"key":"e_1_3_3_6_1","unstructured":"Centers for Disease Control and Prevention . Antibiotic resistance threats in the United States 2013 GA USA (2013). www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013\u20132508.pdf#pageD11 ."},{"key":"e_1_3_3_7_1","unstructured":"Tacconelli E MagriniN CarmeliYet al. Global priority list of antibiotic-resistant bacteria to guide research discovery and development of new antibiotics. WHO (2017). www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1 ."},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05035-11"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03514.x"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06268-11"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02166-13"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis588"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.11.001"},{"key":"e_1_3_3_14_1","unstructured":"Generating antibiotic incentives now . Food and Drug Administration Safety and Innovation Act (2018). www.fda.gov\/downloads\/aboutfda\/centersoffices\/officeofmedicalproductsandtobacco\/cder\/ucm595188.pdf ."},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00883-17"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw636"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02097-16"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01165-15"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02101-17"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02534-16"},{"key":"e_1_3_3_22_1","unstructured":"Meropenem\u2013vaborbactam package insert. The Medicines Company NJ USA."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199528040-00002"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03742.x"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.2.129"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.7.1577"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00127"},{"issue":"61","key":"e_1_3_3_28_1","article-title":"Vaborbactam: spectrum of \u03b2-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae","volume":"24","author":"Lomovskaya O","year":"2017","unstructured":"Lomovskaya O , SunD, Rubio-AparicioDet al. Vaborbactam: spectrum of \u03b2-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob. Agents Chemother.24 (61), pii:e01443-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00711-16"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00567-17"},{"issue":"62","key":"e_1_3_3_31_1","article-title":"Activity of meropenem\u2013vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae","volume":"21","author":"Hackel MA","year":"2017","unstructured":"Hackel MA , LomovskayaO, DudleyMN, KarlowskyJA, SahmDF . Activity of meropenem\u2013vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob. Agents Chemother.21 (62), pii:e01904-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"61","key":"e_1_3_3_32_1","article-title":"Meropenem\u2013vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae","volume":"22","author":"Sun D","year":"2001","unstructured":"Sun D , Rubio-AparicioD, NelsonK, DudleyMN, LomovskayaO . Meropenem\u2013vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother.22 (61), pii:e01694-17 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.2.480-484.2001"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0267-8"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0438"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02418-12"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.2"},{"issue":"62","key":"e_1_3_3_38_1","article-title":"Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in vitro hollow-fiber model","volume":"25","author":"Sabet M","year":"2018","unstructured":"Sabet M , TaraziZ, Rubio-AparicioDet al. Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in vitro hollow-fiber model. Antimicrob. Agents Chemother.25 (62), pii:e01969-17 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00568-16"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01713-15"},{"key":"e_1_3_3_41_1","volume-title":"2nd ASM Microbe","author":"Trang M","year":"2017","unstructured":"Trang M , GriffithDC, BhavnaniSMet al. Population pharmacokinetics of meropenem and vaborbactam in healthy volunteers and infected patients. Presented at : 2nd ASM Microbe . New Orleans, LA, USA, 1\u20135 June 2017 ."},{"key":"e_1_3_3_42_1","volume-title":"2nd ASM Microbe","author":"Bhavnani SM","year":"2017","unstructured":"Bhavnani SM , HammelJP, RubinoCMet al. Meropenem\u2013vaborbactam pharmacokinetic pharmacodynamic analyses for efficacy based on data from patients enrolled in Phase III studies. Presented at : 2nd ASM Microbe . New Orleans, LA, USA, 1\u20135 June 2017 ."},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02103-17"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1086\/590064"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.06.014"},{"key":"e_1_3_3_46_1","volume-title":"2nd ASM Microbe","author":"Griffith DC","year":"2017","unstructured":"Griffith DC , SabetM, TaraziZ, LomovskayaO, DudleyMN . Pharmacodynamics of vaborbactam when administered in combination with meropenem. Presented at : 2nd ASM Microbe . New Orleans, LA, USA, 1\u20135 June 2017 ."},{"key":"e_1_3_3_47_1","volume-title":"ID Week","author":"Kaye KS","year":"2017","unstructured":"Kaye KS , VazquezJ, MathersAet al. Meropenem\u2013vaborbactam (vabomere) vs best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: pooled population analysis across infection types. Presented at : ID Week . San Diego, CA, USA, 4\u20138 October 2017 ."},{"key":"e_1_3_3_48_1","unstructured":"Meropenem package insert . AstraZeneca DE USA ."},{"key":"e_1_3_3_49_1","volume-title":"IDWeek","author":"McKinnell JA","year":"2017","unstructured":"McKinnell JA , ConnollyL, PushkinR, JubbAMet al. Improved outcomes with plazomicin compared with colistin in patients with bloodstream infections caused by carbapenem-resistant Enterobacteriaceae (CRE): results from the CARE study. Presented at : IDWeek . San Diego, CA, USA, 4\u20138 October 2017 ."},{"key":"e_1_3_3_50_1","volume-title":"2nd ASM Microbe","author":"Lomovskaya O","year":"2017","unstructured":"Lomovskaya O , TsivkovskiR . Vaborbactam (VAB) is not affected by KPC-2 and KPC-3 variants containing Asp179Tyr amino acid substitution that are resistant to ceftazidime (CAZ) potentiation with avibactam. Presented at : 2nd ASM Microbe . New Orleans, LA, USA, 1\u20135 June 2017 ."}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2018-0054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:38:03Z","timestamp":1719124683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2018-0054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,25]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.2217\/fmb-2018-0054"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2018-0054","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}